Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790919 · ClinicalTrials.gov registry record · Phase 2
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
A Phase 2 study of Major Depressive Disorder (MDD), sponsored by University of California, Berkeley.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT01790919 is a Phase 2 study of Major Depressive Disorder (MDD) that has completed, run by University of California, Berkeley. The registered enrollment target is 48 participants, below the 156-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01790919, a Phase 2 study of Major Depressive Disorder (MDD), has completed, sponsored by University of California, Berkeley.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Existing drug and talking therapies for major depressive disorder (MDD) fail to produce complete recovery. This study will determine if substantial improvements to one of the most promising therapies, cognitive therapy (CT), can be achieved by administering a carefully designed procedure to improve memory for the content of CT sessions. This is important because (a) memory deficits are common in MDD patients and (b) each CT therapy session typically covers a complex array of topics and various skills are taught.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive therapy for depression
Study Locations (1)
California
- University of California, Berkeley - Berkeley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01790919
The ClinicalTrials.gov registry entry for NCT01790919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (69% lower). The listed sponsor is University of California, Berkeley, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 1 intervention - of which Cognitive therapy for depression is the first listed.
NCT01790919 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01790919 about?
NCT01790919 is a clinical study titled "Improving Depression Outcome by Enhancing Memory for Cognitive Therapy". Existing drug and talking therapies for major depressive disorder (MDD) fail to produce complete recovery. This study will determine if substantial improvements to one of the most promising therapies, cognitive therapy (CT), can be achieved by administering a carefully designed procedure to improve ...
What is the current status of trial NCT01790919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2013-02. Estimated completion is 2015-03.
What conditions does trial NCT01790919 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT01790919?
The interventions under investigation include: Cognitive therapy for depression (BEHAVIORAL).
Who is sponsoring clinical trial NCT01790919?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01790919 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
-
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RECRUITING · Phase 2
-
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
ACTIVE NOT RECRUITING · Phase 2
-
A Study in Patients With Major Depressive Disorder
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.